To investigate the role of DUSPs in transdifferentiation of metastatic melanoma cells and their response to MAPKi, we selected two BRAF(V600E) mutant human metastatic melanoma cell lines––MRA5 is intrinsically resistant to both BRAFi and MEKi, while MRA6 is sensitive to both inhibitors. Here, BRAF is linked to metastatic melanoma.